cagrilintide trial Once-weekly for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 New in the August 14,
New in the August 14, 2025, issue of NEJM: CagrilintideSemaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) CagrilintideSemaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) Cagrilintide Dosing: Complete Protocol Guide & Titration SeekPeptides In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth cagrilintide
Pay in 4 interest-free payments of $6.11 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



